EUCTR2016-003874-42-GB进行中（未招募）1 期
A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency - N/A
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Pre-pubertal children aged =3 years , and not yet 11 years for girls (10 years and 364 days) or not yet 12 years (11 years and 364 days) for boys, (on the date of ICF signature), with either isolated GHD, or GH insufficiency as part of multiple pituitary hormone deficiency.
- •2. Confirmed diagnosis of GHD by two different GH provocation tests defined as a peak plasma GH level of =10 ng/mL, determined by local or central laboratory using a validated assay . Global study MM may accept prior local laboratory results; subject to pre-approval and if the tests were conducted as recommended in the protocol
- •3. BA is not older than CA and should be < 10 for girls and < 11 for boys.
- •4. Without prior exposure to any recombinant hGH (r-hGH) therapy (naïve patients).
- •5. Impaired Ht velocity defined as:
- •Annualized height velocity (HV) below the 25th percentile for CA (HV < -0.7 SDS) and gender according to the OPKO HV (Tanner, Prader and Hermanussen) calculator, provided
- •The interval between 2 Ht measurements should be at least 6 months, but should not exceed, 18 months prior to inclusion.
- •6. Baseline IGF-1level of at least 1 standard deviation (SD) below the mean IGF-1 level standardized for age and sex (IGF-I SDS =-1) according to the central laboratory reference values. A single re-test will be allowed (subject to discussion with MM) if all other criteria are met.
- •7. Normal calculated glomerular filtration rate (GFR) based on updated bedside” Schwartz formula for pediatric patients (calculation is recommended below):
- •Creatine Clearance Rate (CrCL) (mL/min/1.73 m2) =0.413 * *Ht / /serum creatine (Scr)
- •Scr: in mg/dL;
- •8. Children with multiple hormonal deficiencies must be on stable replacement therapies (no change in dose) for other hypothalamo-pituitary organ axes for at least 3 months prior to ICF signing
- •9. Normal 46XX karyotype for girls.
- •10. Willing and able to provide written informed consent of the parent or legal guardian of the patient and written assent from pediatric patients (where applicable based on age and country regulation).
- •Inclusion into the LT-OLE: 11. Completion of the main study (12 months of treatment) with adequate compliance. 12. Willing and able to provide written informed consent of the parent or legal guardian of the patient and written assent from pediatric patients (where applicable based on age and country regulation). 13. Agreement to refrain from sexual activity during the LT-OLE i.e. observe complete sexual abstinence as the only acceptable contraceptive measure during the LT-OLE (for pubertal and post-pubertal patients).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 220
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Children with prior history of leukemia, lymphoma, sarcoma or any other forms of cancer.
- •2. History of radiation therapy or chemotherapy
- •3. Malnourished children defined as BMI < -2 SDS for age and sex
- •4. Children with psychosocial dwarfism
- •5. Children born small for gestational age (SGA – birth weight and/or birth length <-2 SDS for gestational age)
- •6. Presence of anti-hGH Ab at screening
- •7. Any clinically significant (CS) abnormality likely to affect growth or the ability to evaluate growth, such as, but not limited to, chronic diseases like renal insufficiency, spinal cord irradiation, etc.
- •8. Types 1 and2 diabetic patients who, in the opinion of the investigator, are not receiving standard of care treatment, or are non-compliant with their prescribed treatment or who are in poor metabolic control(criteria for controlled diabetes are defined in Appendix F of the protocol).
- •9. Chromosomal abnormalities including Turner’s syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, SHOX mutations/deletions and skeletal dysplasias.
- •10. Concomitant administration of other treatments that may have an effect on growth such as anabolic steroids, or sex steroids, with the exception of Attention-Deficit/Hyperactivity Disorder (ADHD) drugs or hormone replacement therapies (thyroxin, hydrocortisone, desmopressin [DDAVP]) ®]).
- •11. Children requiring glucocorticoid therapy (e.g. for asthma) that are taking chronically a dose greater than 400 µg/day of inhaled budesonide or equivalent
- •12. Major medical conditions and/or presence of contraindication to r-hGH treatment.
- •13. More than 1 closed epiphyses
- •14. Known or suspected Human Immunodeficiency Virus (HIV-)-positive patient, or patient with advanced diseases such as Acquired Immunodeficiency Syndrome (AIDS) or tuberculosis.
- •15. Drug, substance, or alcohol abuse.
- •16. Known hypersensitivity to the components of study medication.
- •17. Other causes of short stature such as celiac disease, uncontrolled primary hypothyroidism and rickets.
- •18. The patient and/or the parent/legal guardian are likely to be non-compliant in respect to study conduct.
- •19. Participation in any other study of an investigational agent within 30 days prior to ICF signature (including administration of investigational agent).
- •20. Study enrollment requirements have been met or the study has been closed by the Sponsor prior to the completion of screening process.
- •Exclusion during the LT-OLE: 21. Concomitant administration of other treatments that may have an effect on growth such as anabolic steroids, or sex steroids (other than for hormonal replacement), with the exception of ADHD drugs or hormone replacement therapies (thyroxin, hydrocortisone, testosterone, estrogen/progesterone, desmopressin [DDAVP®]) 22. Change in medical condition during the treatment period (such as, but not limited to, development of a serious inter-current critical illness, a severe adverse drug reaction, etc.) 23. Positive pregnancy test. 24. Unresolved drug related (MOD-4023 or Genotropin®) SAE from the treatment period as per MM judgement.
研究者
相似试验
进行中（未招募）
1 期
An efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiencyGrowth hormone deficiency in pre-pubertal childrenMedDRA version: 19.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-003874-42-DEOPKO Biologics Ltd.220
进行中（未招募）
1 期
An efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiencyGrowth hormone deficiency in pre-pubertal childrenMedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-003874-42-BGOPKO Biologics Ltd.220
进行中（未招募）
1 期
An efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiencyGrowth hormone deficiency in pre-pubertal childrenMedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-003874-42-ITPRM|21097220
进行中（未招募）
1 期
An efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiencyGrowth hormone deficiency in pre-pubertal childrenMedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-003874-42-PLOPKO Biologics Ltd.220
进行中（未招募）
1 期
An efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiencyEUCTR2016-003874-42-ESOPKO Biologics Ltd.220